BioCentury | Dec 2, 2016
Company News

Inisync sales and marketing update

...Takeda launched Inisync alogliptin/metformin in Japan to treat Type II diabetes. The recommended dose is a...
...Type II diabetes. The recommended dose is a once-daily tablet consisting of 25 mg of alogliptin...
BioCentury | Oct 17, 2016
Clinical News

Kazano regulatory update

...NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin...
...the U.S. and as Vipdomet in the EU for the indication. Furiex Pharmaceuticals Inc. co-developed alogliptin...
...Dublin, Ireland Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Kazano ( Vipdomet - EU) alogliptin/metformin...
BioCentury | Jun 10, 2015
Clinical News

Merck reports data from Januvia CVOT

...two DPP-4 inhibitors to treat diabetes: Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Nesina alogliptin...
...a statistically significant 27% increase in hospitalization for heart failure and in a separate CVOT, Nesina...
BioCentury | Apr 29, 2015
Company News

Merck's Januvia meets in CV outcomes trial

...plc (LSE:AZN; NYSE:AZN) showed a statistically significant 27% increase in hospitalization for heart failure. Nesina alogliptin...
BioCentury | Apr 27, 2015
Regulation

CVOT crossroads

...EXAMINE cardiovascular outcomes trials of the DPP-4 inhibitors Onglyza saxagliptin from AstraZeneca plc and Nesina alogliptin...
...Readjudicated data from the RECORD outcomes study exonerated Avandia, yet the guidance remains. Onglyza and Nesina...
...a history of cardiovascular disease or multiple risk factors for vascular disease, including renal failure. Nesina...
BioCentury | Apr 20, 2015
Clinical News

Nesina alogliptin regulatory update

...to treat diabetes -- Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) and Nesina alogliptin...
...panel analyzed the data from 2 CV outcomes trials, SAVOR for Onglyza and EXAMINE for Nesina...
...Onglyza in Japan. Takeda Pharmaceutical Co. Ltd . (Tokyo:4502), Osaka, Japan Product: Nesina alogliptin ( SYR-322...
BioCentury | Apr 20, 2015
Clinical News

Onglyza saxagliptin regulatory update

...DPP-4 ; CD26 ) inhibitors to treat diabetes -- Onglyza saxagliptin from AstraZeneca and Nesina alogliptin...
...panel analyzed the data from 2 CV outcomes trials, SAVOR for Onglyza and EXAMINE for Nesina...
...had a statistically significant 27% increase in hospitalization for heart failure in SAVOR. Patients taking Nesina...
BioCentury | Apr 15, 2015
Company News

FDA panel backs label changes to DPP-4 inhibitors

...DPP-4 inhibitors to treat diabetes -- Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Nesina alogliptin...
...panel analyzed the data from two cardiovascular outcomes trials, SAVOR for Onglyza and EXAMINE for Nesina...
...had a statistically significant 27% increase in hospitalization for heart failure in SAVOR. Patients taking Nesina...
BioCentury | Apr 10, 2015
Top Story

FDA committee to discuss CV risks of DPP-4s

...overall safety data. AZ's SAVOR trial of Onglyza saxagliptin and Takeda's EXAMINE trial of Nesina alogliptin...
...a separate document, the agency said data from Takeda's 5,400-patient EXAMINE trial appeared consistent with Nesina's...
...a fixed-dose combination of alogliptin and Takeda's Actos pioglitazone . FDA approved all three alogliptin...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...approved in Canada in 2014) $67.0 Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Nesina alogliptin (Vipidia) and alogliptin...
Items per page:
1 - 10 of 123